Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-09-05
2009-06-09
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C514S252180
Reexamination Certificate
active
07544799
ABSTRACT:
The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumour therapy.
REFERENCES:
patent: 3887551 (1975-06-01), Crisp et al.
patent: 3905959 (1975-09-01), Nakanishi
patent: 3956279 (1976-05-01), Binderup et al.
patent: 4061853 (1977-12-01), Urech
patent: 4351832 (1982-09-01), Rakhit et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5985893 (1999-11-01), Yu et al.
patent: 6048866 (2000-04-01), Hutchings et al.
patent: 6894051 (2005-05-01), Zimmermann et al.
patent: WO 85/00604 (1985-02-01), None
Carter et al., Chemotherapy of Cancer, second edition, John Wiley & Sons, N.Y., N.Y., 1981, pp. 362-365.
Carroll et al., www.bloodjournal.org at Novartis Farma Bham, Oct. 2008, pp. 4947-4952.
Hollis Showalter H.D. et al., “Small Molecule Inhibitors of the Platelet-Derived Growth Factor Receptor, the Fibroblast Growth Factor Receptor, and Src Family Tyrosine Kinases,” Pharmacol. Ther., vol. 76, Nos. 1-3, pp. 55-71 (1997).
Davey, R.J. et al., “Polymorphism in Molecular Crystals: Stabilization of a Metastable Form by Conformation Mimicry,” J. Am. Chem. Soc. 1997, vol. 119, pp. 1767-1772 (1997).
Myllärniemi Marjukka et al., “Selective Tyrosine Kinase Inhibitor for the Platelet-Derived Growth Factor Receptor In Vitro Inhibits Smooth Muscle Cell Proliferation After Reinjury of Arterial Intima In Vivo,” Cardiovascular Drugs and Therapy, vol. 13, pp. 159-168 (1999).
Byrn, Stephen et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, vol. 12, No. 7, pp. 945-954 (1995).
Radebough, Galen W., “Preformulation,” Remington: The Science and Practice of Pharmacy, 20thEdition, Chapter 83, pp. 1447-1462 (2000).
Zimmermann, Jürg et al., “Potent and Selective Inhibitors of the Abi-Kinase: Phenylaminopyrimidine (PAP) Derivatives,”Bioorganic & Medicinal Chemistry Letters, vol. 7(2), pp. 187-192 (1997).
Bilder et al., “Inhibitors of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase,” Cardiovascular Drug Reviews, vol. 14, No. 4, pp. 380-399 (1996).
Buchdunger et al., “Selective inhibition of the platelet-derived growth facgtor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class” Proc. Natl. Acad. Sci., USA, vol. 92, pp. 2258-2562 (1995).
Buchdunger et al., “Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivatives,” Cancer Research, pp. 100-104, Jan. 1, 1996.
Raymond et al., “Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC:NDDG/BTG Intergroup Study,” Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings, vol. 22(14S), Abstract 1501 (2004).
Wen et al., “Phase I study of STI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTRC 99-08),” Journal of Clinical Oncology, 2002 ASCO Annual Meeting, Abstract 288 (2002).
Wen et al., “Phase I/II Study of Imatinib Mesylate (STI571) for Patients with Recurrent Malignant Gliomas (NABTC 99-08),” Society of Neuro-Oncology 9thAnnual Meeting 2004, Abstract TA63 (2004).
Kilic et al., “Intracranial Inhibition of Platelet-derived Growth Factor-mediated Glioblastoma Cell Growth by an Orally Active Kinase Inhibitor of the 2-Phenylaminopyrimidine Class,” Cancer Research, 60, pp. 5143-5150 (2000).
Zografi et al., “Interfacial Phenomena,” Remington Pharmaceutical Sciences, 18thEdition, Chapt. 19, pp. 257, 275, 276 (1990).
Jendrossek et al., “Novel Chemotherapeutic Agents for the Treatment of Glioblastoma Multiforme,” Expert Opinions on Investigational Drugs, p. 1899-1924 (2003).
Bürger Hans M
Sutter Bertrand
Zimmermann Jörg
Dohmann George R.
Kumar Shailendra
Novartis AG
LandOfFree
Crystal modification of a N-phenyl-2-pyrimidineamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystal modification of a N-phenyl-2-pyrimidineamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal modification of a N-phenyl-2-pyrimidineamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4120800